SCHEMBL4433895

SCHEMBL4433895

Cc1ccc(N(C(=O)OC(C)(C)C)C2CCNCC2)c([N+](=O)[O-])c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
GAA P10253 2/20 0.39
MCOLN3 Q8TDD5 1/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 2/20 0.36
CYP3A4 P08684 1/20 0.36
SLC6A4 P31645 3/20 0.34
SLC6A2 P23975 2/20 0.34
TACR1 P25103 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP2D6 P10635 1/20 0.34
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HCAR3 P49019 1/20 0.33
IDO1 P14902 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4434425 0.92 KDM4E (0.39) KDM4EGAAMCOLN3ALDH1A1TP53
SCHEMBL4434450 0.88 TACR1 (0.38) ALDH1A1SLC6A4SLC6A2TACR1MEN1
SCHEMBL4444516 0.88 MAPK1 (0.40) ALDH1A1SLC6A4SLC6A2TACR1MEN1
SCHEMBL4434892 0.88 MCOLN3 (0.35) KDM4EGAAMCOLN3ALDH1A1TP53
SCHEMBL4439400 0.88 POLB (0.40) KDM4EGAAMCOLN3ALDH1A1MEN1
SCHEMBL4437504 0.88 MAPT (0.45) ALDH1A1CYP3A4TACR1MEN1KMT2A
SCHEMBL4437157 0.88 HCAR3 (0.39) KDM4EGAACYP3A4MEN1KMT2A
SCHEMBL4445145 0.87 CYP2C9 (0.41) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL4434940 0.86 MEN1 (0.39) KDM4ETP53MEN1KMT2ACYP2D6
SCHEMBL4438391 0.86 KMT2A (0.36) KDM4EALDH1A1TP53TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132177-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-12-16 EP disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 WO disclosed